Munich Re's Buyback Machine Grinds On as Goldman Trims Its Ambitions

Goldman Sachs trims Munich Re price target to €533, but strong Q2 profits and ongoing buybacks create a mixed investment case.

The signal from Munich Re's management and the message from Goldman Sachs are pulling in opposite directions — and that tension now defines the investment case for Germany's largest reinsurer.

Goldman cut its price target on the stock from 557 to 533 euros while keeping a "Neutral" rating, a move that arrived just days after Munich Re published its half-year results and lowered its revenue guidance. The revised target still sits above the current share price, but the adjustment marks a clear cooling of expectations from one of Wall Street's most closely watched houses.

The stock closed Monday at 515.40 euros, down 0.4 percent on the day. Over the past month, the shares have barely budged, though they remain 8.3 percent lower since the start of the year. At its October peak of 575.40 euros — the 52-week high — the stock now trades roughly 10 percent below that mark.

A Buyback Program That Won't Quit

While analysts trim their forecasts, Munich Re keeps buying its own paper with steady hands. Between August 7 and 14, the company repurchased 127,500 shares on Xetra at a weighted average price ranging from 511.53 to 517.83 euros. That brings the total bought back since the program launched on May 14 to 1,539,124 shares.

The buyback is a classic signal of management confidence in the company's valuation — a quiet counterweight to the more cautious voices in the analyst community. For income-focused investors, the ongoing capital return program provides a degree of stability even as the near-term price action remains subdued.

The Numbers Behind the Debate

The timing of Goldman's move is telling. It followed Munich Re's decision to trim its 2026 revenue target from 64 billion to 62 billion euros, with the reinsurance division's goal cut from 40 billion to 38 billion euros. Crucially, the company left its full-year profit forecast unchanged at 6.3 billion euros — a mixed signal that Goldman appears to have translated into a lower, though still constructive, price target.

The operational picture, however, remains robust. Second-quarter net profit came in at 2.211 billion euros, up from 2.085 billion euros a year earlier and comfortably ahead of the 1.786 billion euros analysts had expected. First-half net profit reached 3.922 billion euros, with a return on equity of 23 percent. Major loss costs ran at just 4.9 percent of insurance revenue — exceptionally low and a key support for earnings quality even as the revenue outlook softens.

A Sector Out of Step

The broader reinsurance landscape tells a more nuanced story than a simple downgrade cycle. On the same day Goldman trimmed Munich Re, it raised its price target on Talanx from 137 to 141 euros and upgraded the stock to "Buy," citing higher valuations for primary insurance. The bank left its view on Hannover Re unchanged, while Jefferies held Zurich Insurance at "Hold" with a 520-franc target.

That divergence suggests the caution on Munich Re is company-specific rather than a blanket sector call. Jefferies analyst Philip Kett, in his monthly industry review, kept a "Hold" rating on Munich Re with a 600-euro target — well above Goldman's new mark. JPMorgan, meanwhile, reaffirmed "Overweight" with a 590-euro target on August 7, immediately after the results.

The spread between 533 and 600 euros illustrates just how differently the street weighs the combination of solid earnings and softer revenue guidance.

Two Faces, One Stock

With a relative strength index of 54, the shares sit in neutral territory — neither overbought nor oversold — and trade barely one percent below their 200-day moving average of 519.87 euros.

For investors, Munich Re remains a story with two narratives running in parallel. The earnings power is demonstrably intact, and the buyback program signals that management shares that view. But the lowered revenue targets raise legitimate questions about growth momentum in new business, and Goldman's trimmed price target keeps that debate front and center.

The coming weeks will show which force wins out: the analyst skepticism or the company's own conviction.